Mental-health conditions, specialty meds driving drug plan cost increases in 2019: report
Staff | July 9, 2020 Private drug plans saw the largest yearly increase in their average eligible costs in 2019, according to Telus Health’s annual drug trends report. The report attributed the rise to a jump in the use and cost of specialty drugs and a growth in younger Canadians using medication for mental-health challenges. It also noted the repeal of the OHIP+ program in Ontario and an increase in overall costs for traditional drugs also contributed to the 7.6 per cent spike in private plans’ eligible monthly costs across all plan members. This is well up from a decline of 3.6 per cent in 2018. Provincially, Ontario saw the highest spike in eligible costs at 10.2 per cent, largely attributed to the OHIP+ rollback — but, Telus Health noted, when it removed costs for plan members under age 25, eligible costs in the province had still increased 5.4 per cent, compared to a 2.4 per cent drop in 2018. Quebec saw cost increases of 5.8 per cent (up from a three per cent increase in 2018), followed by the Atlantic provinces (4.2 per cent, up from a 1.1 per cent decrease in 2018) and western provinces (four per cent, up from a 0.3 per cent drop in...